|
rs1554389088
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause Intellectual Disability.
|
29100089 |
2017 |
|
rs139455627
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Mutations in TSPEAR, Encoding a Regulator of Notch Signaling, Affect Tooth and Hair Follicle Morphogenesis.
|
27736875 |
2016 |
|
rs1569151872
|
|
AA |
0.700 |
GeneticVariation |
CLINVAR |
Mutations in TSPEAR, Encoding a Regulator of Notch Signaling, Affect Tooth and Hair Follicle Morphogenesis.
|
27736875 |
2016 |
|
rs752513525
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Mutation in NDUFA13/GRIM19 leads to early onset hypotonia, dyskinesia and sensorial deficiencies, and mitochondrial complex I instability.
|
25901006 |
2015 |
|
rs1064794533
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
|
rs146539065
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
|
rs147484110
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs1563945076
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs267606670
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs74315442
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs776969714
|
|
GC |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs796052243
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
|
rs864309483
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs34637584
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Further, G2019S carriers had higher LEDD (MD: 115.20; <i>p</i> < 0.00001) and were more likely to develop motor complications, such as dyskinesia and motor fluctuations (OR: 2.18, 2.02; <i>p</i> < 0.00001, 0.04) than non-carriers.
|
30283330 |
2018 |
|
rs34637584
|
|
|
0.050 |
GeneticVariation |
BEFREE |
No association was found between the G2019S mutation and the Mini Mental State Examination scores (MMSE), and MC patients appeared more susceptible to dyskinesia than NC patients.
|
26831335 |
2016 |
|
rs34637584
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The G2019S mutation carriers showed a non significant increase in dyskinesias, and 2/3 developed Dopamine Dysregulation Syndrome and visual hallucinations.
|
23340200 |
2013 |
|
rs34637584
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
|
22703868 |
2012 |
|
rs34637584
|
|
|
0.050 |
GeneticVariation |
BEFREE |
All patients carrying the LRRK2 G2019S exhibited typical levodopa-responsive parkinsonism, and severe levodopa-induced dyskinesia was observed in the patient carrying the LRRK2 and parkin mutations.
|
17388990 |
2007 |
|
rs6265
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Carriers of DRD2 risk haplotypes and possibly the BDNF variants rs6265 and DRD3 haplotypes, were at increased risk of dyskinesia, suggesting that these genes may be involved in dyskinesia related pathomechanisms.
|
29191473 |
2018 |
|
rs6265
|
|
|
0.030 |
GeneticVariation |
BEFREE |
BDNF Val66Met and spontaneous dyskinesias in non-clinical psychosis.
|
22766130 |
2012 |
|
rs6265
|
|
|
0.030 |
GeneticVariation |
BEFREE |
BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
|
18977816 |
2009 |
|
rs6280
|
|
|
0.030 |
GeneticVariation |
BEFREE |
To investigate the association between orofaciolingual (TDof) and limb-truncal dyskinesias (TDlt) and Ser9Gly (DRD3), -1438G>A (HTR2A), and Cys23Ser (HTR2C) polymorphisms in Russian psychiatric inpatients from Tomsk, Siberia.
|
19439249 |
2009 |
|
rs6280
|
|
|
0.030 |
GeneticVariation |
BEFREE |
As recent observations indicate the dopamine D(3) receptor (DRD3) to modulate both therapeutic action of levodopa and dyskinesia, we reappraised the impact of the DRD3 Ser9Gly polymorphism on development of motor complications in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease.
|
19353703 |
2009 |
|
rs6280
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Chinese Han patients with schizophrenia were assessed for abnormal involuntary movements, and subgroups of 42 patients with persistent tardive dyskinesia and 59 consistently without dyskinesias were assessed for the DRD3 ser9gly and the MnSOD ala-9val polymorphisms.
|
12960753 |
2003 |
|
rs628031
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Furthermore, clinical-pharmacogenetic model for prediction of time to occurrence of dyskinesia included female sex (HR = 1.07), age at diagnosis (HR = 0.97), tremor-predominant Parkinson's disease (HR = 0.88), beta-blockers (HR = 0.95), alcohol consumption (HR = 0.99), time from diagnosis to initiation of levodopa treatment (HR = 1.15), <i>CAT</i> rs1001179 (HR = 1.27), <i>SOD2</i> rs4880 (HR = 0.95), <i>NOS1</i> rs2293054 (HR = 0.99), <i>COMT</i> rs165815 (HR = 0.92), and <i>SLC22A1</i> rs628031 (HR = 0.80).
|
31156712 |
2019 |